Daily Market Reports | May 26 2026
This story features ALCIDION GROUP LIMITED, and other companies.
For more info SHARE ANALYSIS: ALC
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
ALC AUE CDA CGF CY5 EGL GYG IPG MXI OCA PV1 SHV TLX
ALC ALCIDION GROUP LIMITED
Healthcare services – Overnight Price: $0.11
Canaccord Genuity rates ((ALC)) as Buy (1) –
Canaccord Genuity retains a Buy rating for Alcidion Group with a $0.14 target price following the execution of a major healthcare contract.
A seven-year agreement with University Hospitals Sussex to deploy the Miya Precision platform secures a total contract value of $35m, with modular extension optionality up to $49m over ten years.
The immediate implementation phase underpins FY26 revenue guidance of at least $50m and drives an upgrade to near-term operating earnings estimates, despite a modest gross margin dilution reflecting third-party module costs.
The transaction serves as a critical de-risking event that validates the company’s United Kingdom expansion strategy and reinforces its ability to secure large-scale competitive tenders, the broker notes.
This report was published on May 25, 2026.
Target price is $0.14 Current Price is $0.11 Difference: $0.03
If ALC meets the Canaccord Genuity target it will return approximately 27% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
AUE AURUM RESOURCES LIMITED
Gold & Silver – Overnight Price: $0.59
Canaccord Genuity rates ((AUE)) as Speculative Buy (1) –
Canaccord Genuity maintains a Speculative Buy rating for Aurum Resources with a $1.55 target price following the receipt of major environmental approvals for the Boundiali gold project in Cote d’Ivoire.
Commentary states the issuance of three assessment certificates across the mining licence application areas represents a key de-risking milestone and clears the pathway for final regulatory review.
A recent 24% upgrade to indicated resources at the asset to 1.70Moz of contained gold is expected to underpin a pre-feasibility study slated for release this quarter.
The broker estimates the deposit could support an operation delivering 160,000 to 175,000 ounces annually over a ten-year mine life at an all-in sustaining cost around US$1,600/oz.
Aggressive resource growth drilling continues with 16 company-owned diamond rigs operating on site, supported by a $61m cash balance at the end of March 2026.
This report was published on May 25, 2026.
Target price is $1.55 Current Price is $0.59 Difference: $0.96
If AUE meets the Canaccord Genuity target it will return approximately 163% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CDA CODAN LIMITED
Hardware & Equipment – Overnight Price: $40.42
Canaccord Genuity rates ((CDA)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Codan with a $47.05 target price following the $21m acquisition of Adaptive Dynamics.
The engineering firm specialises in preventing communications interference, bringing critical intellectual property applicable to military command, control, and unmanned systems.
The acquired technology will integrate into the existing communications portfolio to support ongoing contract momentum with United States defense forces.
The transaction is expected to be earnings neutral in the first year of ownership and funded entirely through existing cash reserves.
Earnings estimates remain unchanged, while near-term balance sheet projections are adjusted to reflect the upfront consideration and contingent milestone payments.
This report was published on May 25, 2026.
Target price is $47.05 Current Price is $40.42 Difference: $6.63
If CDA meets the Canaccord Genuity target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $42.00, suggesting upside of 3.9%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 90.9, implying annual growth of 59.2%.
Current consensus DPS estimate is 42.1, implying a prospective dividend yield of 1.0%.
Current consensus EPS estimate suggests the PER is 44.5.
Forecast for FY27:
Current consensus EPS estimate is 102.8, implying annual growth of 13.1%.
Current consensus DPS estimate is 48.9, implying a prospective dividend yield of 1.2%.
Current consensus EPS estimate suggests the PER is 39.3.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CGF CHALLENGER LIMITED
Wealth Management & Investments – Overnight Price: $9.35
Jarden rates ((CGF)) as Neutral (3) –
Jarden retains a Neutral rating for Challenger with a $8.70 target price ahead of its annual investor day.
The event is expected to focus on the domestic annuity growth strategy, specifically addressing distribution constraints currently limiting retail sales momentum.
Management is also anticipated to provide further clarity regarding Calix Re, a recently established Bermuda-based reinsurance vehicle expected to provide an offshore growth platform.
The capital deployment framework under revised regulatory standards will be a key topic of interest, with the business holding $442m in distributable surplus capital.
While the forward life margin outlook appears more constructive, the broker remains cautious due to persistent fund management outflows and limited valuation support, leaving earnings estimates unchanged.
This report was published on May 24, 2026.
Target price is $8.70 Current Price is $9.35 Difference: minus $0.65 (current price is over target).
If CGF meets the Jarden target it will return approximately minus 7% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $9.58, suggesting upside of 2.5%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 30.80 cents and EPS of 64.20 cents.
At the last closing share price the estimated dividend yield is 3.29%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 14.56.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 66.2, implying annual growth of 136.4%.
Current consensus DPS estimate is 31.0, implying a prospective dividend yield of 3.3%.
Current consensus EPS estimate suggests the PER is 14.1.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 32.10 cents and EPS of 69.50 cents.
At the last closing share price the estimated dividend yield is 3.43%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.45.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 69.4, implying annual growth of 4.8%.
Current consensus DPS estimate is 34.5, implying a prospective dividend yield of 3.7%.
Current consensus EPS estimate suggests the PER is 13.5.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CY5 CYGNUS METALS LIMITED
Gold & Silver – Overnight Price: $0.12
Canaccord Genuity rates ((CY5)) as Speculative Buy (1) –
Canaccord Genuity retains a Speculative Buy rating for Cygnus Metals Limited with a $0.35 target price following strong high-grade infill drill results from the Golden Eye deposit in Quebec.
Recent assay highlights including 8.4m at 16.3g/t gold equivalent from 135m and 3.6m at 15.7g/t gold equivalent from 218m demonstrate excellent continuity within the shallow gold-rich system.
The 15-hole winter drilling campaign specifically targeted the conversion of inferred resources into the higher-confidence indicated category ahead of a mineral resource update expected in the September quarter of 2026.
Regional drilling at the nearby Gwillim gold target is underway with co-funding from joint venture partner Alamos Gold.
The broker notes a scoping study slated for mid-2026 will build upon previous technical assessments and incorporate updated commodity and cost assumptions.
This report was published on May 25, 2026.
Target price is $0.35 Current Price is $0.12 Difference: $0.23
If CY5 meets the Canaccord Genuity target it will return approximately 192% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
EGL ENVIRONMENTAL GROUP LIMITED
Industrial Sector Contractors & Engineers – Overnight Price: $0.12
Moelis rates ((EGL)) as Buy (1) –
Moelis maintains a Buy rating for Environmental Group with its target price revised to $0.20 following a trading update and earnings guidance downgrade.
Management lowered FY26 earnings before interest, tax, depreciation and amortisation guidance to a range between $8.5m and $9.0m, reflecting a combined -$4m impact across the energy and Baltec divisions.
The energy segment downgrade stems from operational matters, historical job balances, and higher fleet diesel costs, despite ongoing customer demand supporting underlying revenue growth, commentary highlights.
The Baltec division suffered from delayed deliveries, logistics disruptions, and slower tender awards from the Middle East, with affected product deliveries deferred into FY27.
Clean air and waste segments continue to trade in line with expectations, providing the broker sufficient confidence to retain a positive long-term investment view despite near-term earnings reductions.
This report was published on May 25, 2026.
Target price is $0.20 Current Price is $0.12 Difference: $0.08
If EGL meets the Moelis target it will return approximately 67% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 24.00.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.00.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
GYG GUZMAN Y GOMEZ LIMITED
Food, Beverages & Tobacco – Overnight Price: $19.86
Jarden rates ((GYG)) as Neutral (3) –
Jarden retains a Neutral rating for Guzman y Gomez with its target price increased to $17.60 from $17.30 following a corporate trading update.
The strategic decision to exit the United States market is seen as signaling capital discipline and a renewed focus on maximising shareholder returns.
The exit involves one-off costs between -US$30m and -US$40m, although the actual cash impact is expected to remain below -US$15m.
Strong Australian operating earnings guidance of approximately $85m drives modest upgrades to core domestic estimates, despite indications of a near-term slowing in fourth-quarter comparable sales.
Surging digital transaction volumes and targeted promotional programs continue to offset a potential moderation in drive-thru demand stemming from elevated cost-of-living pressures, the broker notes.
This report was published on May 22, 2026.
Target price is $17.60 Current Price is $19.86 Difference: minus $2.26 (current price is over target).
If GYG meets the Jarden target it will return approximately minus 11% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $25.41, suggesting upside of 27.9%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 5.40 cents and EPS of 17.70 cents.
At the last closing share price the estimated dividend yield is 0.27%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 112.20.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 22.0, implying annual growth of 54.3%.
Current consensus DPS estimate is 12.1, implying a prospective dividend yield of 0.6%.
Current consensus EPS estimate suggests the PER is 90.3.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 30.70 cents and EPS of 45.90 cents.
At the last closing share price the estimated dividend yield is 1.55%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 43.27.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 46.3, implying annual growth of 110.5%.
Current consensus DPS estimate is 27.0, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 42.9.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
IPG IPD GROUP LIMITED
Industrial Sector Contractors & Engineers – Overnight Price: $5.39
Shaw and Partners rates ((IPG)) as Buy (1) –
Shaw and Partners retains a Buy rating for IPD Group with its target price increased to $5.85 from $5.35 following a strong trading update.
Management guides to approximately 19% growth in FY26 earnings before interest and tax, underpinned by record revenue contributions from the CMI division and robust data centre demand.
Operating expenses as a proportion of revenue have reduced following recent integration investments, commentary highlights, leaving the business well-positioned to navigate ongoing volatility in freight and logistics costs.
Earnings forecasts across the medium term are adjusted downwards by less than -2% to align with the revised operating guidance.
This report was published on May 25, 2026.
Target price is $5.85 Current Price is $5.39 Difference: $0.46
If IPG meets the Shaw and Partners target it will return approximately 9% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 14.60 cents and EPS of 29.50 cents.
At the last closing share price the estimated dividend yield is 2.71%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.27.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 16.70 cents and EPS of 33.50 cents.
At the last closing share price the estimated dividend yield is 3.10%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 16.09.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MXI MAXIPARTS LIMITED
Automobiles & Components – Overnight Price: $1.55
Canaccord Genuity rates ((MXI)) as Buy (1) –
Canaccord Genuity retains a Buy rating for MaxiPARTS with its target price decreased to $2.50 from $2.65 following a “resilient” trading update.
Management provided FY26 net profit before tax guidance between $13.4m and $14.1m on revenues of $273m to $278m, reflecting a slowdown in commercial road transport activity from March due to impacts stemming from the Middle East conflict.
The Forch Australia division mitigated some of the core operational impact by maintaining low double-digit growth rates compared to the prior year.
Proactive cost reduction and working capital management initiatives are expected to deliver an improved balance sheet position, with net debt forecast to fall to $2m by the end of FY26.
The broker modestly downgrades near-term earnings forecasts, but views the underlying business operations as sound and capable of sustaining profitability through cyclical softening.
This report was published on May 25, 2026.
Target price is $2.50 Current Price is $1.55 Difference: $0.95
If MXI meets the Canaccord Genuity target it will return approximately 61% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
OCA OCEANIA HEALTHCARE LIMITED
Aged Care & Seniors – Overnight Price: $0.52
Jarden rates ((OCA)) as Neutral (3) –
Jarden retains a Neutral rating for Oceania Healthcare with its target price decreased to NZ$0.72 from NZ$0.84 following an in-line FY26 financial result.
The business achieved a meaningful reduction in net debt to $500m through divestment proceeds and a strong new sales inventory sell-down.
Care bed profitability is improving and overheads remain contained, positioning the company to generate positive pre-interest cash flow from existing operations during FY27.
Despite the resilient operational execution, earnings and valuation forecasts are revised downwards to account for an increase in risk-free rates and a benign near-term unit pricing environment.
A return to dividend payments remains possible in FY28 if cash generation targets are achieved, the broker notes.
This report was published on May 22, 2026.
Current Price is $0.52. Target price not assessed.
The company’s fiscal year ends in March.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 2.01 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 25.92.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 0.26 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 198.47.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
PV1 PROVARIS ENERGY LIMITED
Energy – Overnight Price: $0.01
Research as a Service (RaaS) rates ((PV1)) as No Rating (-1) –
Provaris Energy is entering a critical phase on the commercialisation route, currently in a fabrication phase for its hydrogen tank prototype and, in parallel, progressing its lithium cobalt oxide business.
Research as a Service (RaaS) expects both prototypes could receive approvals in the September quarter and assesses the commercial gap between the lithium cobalt oxide and hydrogen opportunities is closing, with more definition around the lithium cobalt oxide revenue model later in the year.
While the company will not be the only operator in these emerging sectors, achieving delivery on expectations in 2026 should, in the analyst’s view, cement its significant IP early-mover advantage. The base case valuation sits at $0.13.
Research as a Service (RaaS) research doesn’t carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.
This report was published on May 25, 2026.
Target price is $0.13 Current Price is $0.01 Difference: $0.12
If PV1 meets the Research as a Service (RaaS) target it will return approximately 1200% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Research as a Service (RaaS) forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 0.29 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 3.45.
Forecast for FY27:
Research as a Service (RaaS) forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 0.36 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 2.78.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SHV SELECT HARVESTS LIMITED
Agriculture – Overnight Price: $3.75
Jarden rates ((SHV)) as Initiation of coverage with Underweight (4) –
Jarden initiates coverage on Select Harvests with an Underweight rating and a $3.60 target price.
The broker notes a positive long-term outlook for almond prices supported by structural supply constraints in California and resilient global demand.
Operating earnings over the near term face pressure from a strengthening Australian dollar alongside escalating water, fertiliser, and freight costs following a wet domestic harvest.
Management continuity remains a point of uncertainty as the current chief executive officer serves a six-month notice period without a confirmed successor.
While the prevailing orchard maturity profile is optimal, yielding capacity is expected to moderate over the coming decade and prompt a sizable replanting program, the broker adds.
This report was published on May 24, 2026.
Target price is $3.60 Current Price is $3.75 Difference: minus $0.15 (current price is over target).
If SHV meets the Jarden target it will return approximately minus 4% (excluding dividends, fees and charges – negative figures indicate an expected loss).
The company’s fiscal year ends in September.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 6.90 cents and EPS of 28.10 cents.
At the last closing share price the estimated dividend yield is 1.84%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.35.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 11.90 cents and EPS of 28.50 cents.
At the last closing share price the estimated dividend yield is 3.17%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.16.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
TLX TELIX PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $13.43
Canaccord Genuity rates ((TLX)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Telix Pharmaceuticals with a $30.00 target price following insights from its recent investor conference.
The broker reports discussion focused on growth projections for the prostate-specific membrane antigen franchise, driven by pricing and market share gains from the second-generation product Gozellix.
Preliminary research highlights the potential of the licensed AlFluor technology, an 18F-based agent designed to offer a decentralised point-of-care supply chain.
Commentary explains this candidate could challenge centralised incumbents by decoupling production from the morning cyclotron rush and securing a 12.5% uplift in franchise sales.
A late 2027 regulatory filing could support a mid-2028 regulatory approval, perpetuating the successful dual-product commercial strategy through transitional pass-through status from early 2029, the report concludes.
This report was published on May 25, 2026.
Target price is $30.00 Current Price is $13.43 Difference: $16.57
If TLX meets the Canaccord Genuity target it will return approximately 123% (excluding dividends, fees and charges).
Current consensus price target is $26.10, suggesting upside of 94.3%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is -2.9, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Forecast for FY27:
Current consensus EPS estimate is 31.6, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 42.5.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.
Click to view our Glossary of Financial Terms
CHARTS
For more info SHARE ANALYSIS: ALC - ALCIDION GROUP LIMITED
For more info SHARE ANALYSIS: AUE - AURUM RESOURCES LIMITED
For more info SHARE ANALYSIS: CDA - CODAN LIMITED
For more info SHARE ANALYSIS: CGF - CHALLENGER LIMITED
For more info SHARE ANALYSIS: CY5 - CYGNUS METALS LIMITED
For more info SHARE ANALYSIS: EGL - ENVIRONMENTAL GROUP LIMITED
For more info SHARE ANALYSIS: GYG - GUZMAN Y GOMEZ LIMITED
For more info SHARE ANALYSIS: IPG - IPD GROUP LIMITED
For more info SHARE ANALYSIS: MXI - MAXIPARTS LIMITED
For more info SHARE ANALYSIS: OCA - OCEANIA HEALTHCARE LIMITED
For more info SHARE ANALYSIS: PV1 - PROVARIS ENERGY LIMITED
For more info SHARE ANALYSIS: SHV - SELECT HARVESTS LIMITED
For more info SHARE ANALYSIS: TLX - TELIX PHARMACEUTICALS LIMITED